Huangjia Ruangan Granules Receives Approval for Phase III Clinical Trial in Chronic Hepatitis B Fibrosis Treatment

Stock News

Yesterday

Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ) has announced that it recently received the Drug Clinical Trial Supplemental Application Approval Notice issued by the National Medical Products Administration for its Huangjia Ruangan Granules.

Following review, the clinical trial application for Huangjia Ruangan Granules meets the relevant requirements for drug registration. On the basis of further refining the clinical trial protocol, the Company has been granted approval to conduct a Phase III clinical trial for the treatment of liver fibrosis associated with chronic hepatitis B virus infection.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/news/1165786716"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1165786716\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1165786716?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 16:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165786716","market":"sh","top_or_hot":-1,"title":"Huangjia Ruangan Granules Receives Approval for Phase III Clinical Trial in Chronic Hepatitis B Fibrosis Treatment","media":"Stock News","content":"<p><b>Zhejiang Wecome Pharmaceutical Company Limited</b> (<b>300878.SZ</b>) has announced that it recently received the Drug Clinical Trial Supplemental Application Approval Notice issued by the National Medical Products Administration for its Huangjia Ruangan Granules.<br><br>Following review, the clinical trial application for Huangjia Ruangan Granules meets the relevant requirements for drug registration. On the basis of further refining the clinical trial protocol, the Company has been granted approval to conduct a Phase III clinical trial for the treatment of liver fibrosis associated with chronic hepatitis B virus infection.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Huangjia Ruangan Granules Receives Approval for Phase III Clinical Trial in Chronic Hepatitis B Fibrosis Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHuangjia Ruangan Granules Receives Approval for Phase III Clinical Trial in Chronic Hepatitis B Fibrosis Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-15 16:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Zhejiang Wecome Pharmaceutical Company Limited</b> (<b>300878.SZ</b>) has announced that it recently received the Drug Clinical Trial Supplemental Application Approval Notice issued by the National Medical Products Administration for its Huangjia Ruangan Granules.<br><br>Following review, the clinical trial application for Huangjia Ruangan Granules meets the relevant requirements for drug registration. On the basis of further refining the clinical trial protocol, the Company has been granted approval to conduct a Phase III clinical trial for the treatment of liver fibrosis associated with chronic hepatitis B virus infection.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSYK","symbol_name":"PSYK ETF","start_time":0,"source_url":"","article_id":"1165786716","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165786716","pubTimestamp":1789460304,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ) has announced that it recently received the Drug Clinical Trial Supplemental Application Approval Notice issued by the National Medical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300878":"维康药业","PSYK":"PSYK ETF","MDTX":"Corgi MediaTek 2x Daily ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BMED":"iShares Health Innovation Active ETF","BK0239":"医药制造"},"translate_title":"黄加软肝颗粒治疗慢性乙型肝炎纤维化III期临床试验获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300878":1,"MDTX":1,"BMED":1,"IBBJ":1,"IBBQ":1,"PSYK":1},"content_text":"Zhejiang Wecome Pharmaceutical Company Limited (300878.SZ) has announced that it recently received the Drug Clinical Trial Supplemental Application Approval Notice issued by the National Medical Products Administration for its Huangjia Ruangan Granules.Following review, the clinical trial application for Huangjia Ruangan Granules meets the relevant requirements for drug registration. On the basis of further refining the clinical trial protocol, the Company has been granted approval to conduct a Phase III clinical trial for the treatment of liver fibrosis associated with chronic hepatitis B virus infection.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}